Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James B Lorens

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Cell Biology and Toxicology|March 17, 2012
Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell linesEystein Oveland, Line Wergeland, Randi Hovland, et al.
Tissue Engineering. Part A|June 25, 2014
Akt1 activity regulates vessel maturation in a tissue engineering model of angiogenesisMonica Hellesøy, Anna L Blois, Crina E Tiron, et al.
Medchemcomm|August 16, 2018
Adaptive mechanisms of resistance to anti-neoplastic agentsBibiana I Ferreira, Maria K Lie, Agnete S T Engelsen, et al.
Frontiers in Immunology|June 20, 2025
Axl inhibitor-mediated reprogramming of the myeloid compartment of the <i>in vitro</i> tumor microenvironment is influenced by prior targeted therapy treatmentAnisha Datta, Laura C Bahlmann, Diana N Gong, et al.
Immunity|February 5, 2002
Activation of the PKB/AKT pathway by ICAM-2Omar D Perez, Shigemi Kinoshita, Yasumichi Hitoshi, et al.
Oral Oncology|October 29, 2011
S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrestDipak Sapkota, Daniela Elena Costea, Magnus Blø, et al.
Scientific Reports|July 12, 2024
In vivo turnover and biodistribution of soluble AXL: implications for biomarker developmentOlav Tenstad, Eleni Christakou, Linn Hodneland Nilsson, et al.
Frontiers in Immunology|November 19, 2024
Targeting AXL cellular networks in kidney fibrosisSturla M Grøndal, Magnus Blø, Linn I H Nilsson, et al.
British Journal of Haematology|March 8, 2007
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsCamilla Stapnes, Anne P Døskeland, Kimberley Hatfield, et al.
Frontiers in Immunology|September 6, 2024
AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapyAustin Rayford, Fabian Gärtner, Maria P Ramnefjell, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Cell Biology and Toxicology|March 17, 2012
Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell linesEystein Oveland, Line Wergeland, Randi Hovland, et al.
Tissue Engineering. Part A|June 25, 2014
Akt1 activity regulates vessel maturation in a tissue engineering model of angiogenesisMonica Hellesøy, Anna L Blois, Crina E Tiron, et al.
Medchemcomm|August 16, 2018
Adaptive mechanisms of resistance to anti-neoplastic agentsBibiana I Ferreira, Maria K Lie, Agnete S T Engelsen, et al.
Frontiers in Immunology|June 20, 2025
Axl inhibitor-mediated reprogramming of the myeloid compartment of the <i>in vitro</i> tumor microenvironment is influenced by prior targeted therapy treatmentAnisha Datta, Laura C Bahlmann, Diana N Gong, et al.
Immunity|February 5, 2002
Activation of the PKB/AKT pathway by ICAM-2Omar D Perez, Shigemi Kinoshita, Yasumichi Hitoshi, et al.
Oral Oncology|October 29, 2011
S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrestDipak Sapkota, Daniela Elena Costea, Magnus Blø, et al.
Scientific Reports|July 12, 2024
In vivo turnover and biodistribution of soluble AXL: implications for biomarker developmentOlav Tenstad, Eleni Christakou, Linn Hodneland Nilsson, et al.
Frontiers in Immunology|November 19, 2024
Targeting AXL cellular networks in kidney fibrosisSturla M Grøndal, Magnus Blø, Linn I H Nilsson, et al.
British Journal of Haematology|March 8, 2007
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsCamilla Stapnes, Anne P Døskeland, Kimberley Hatfield, et al.
Frontiers in Immunology|September 6, 2024
AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapyAustin Rayford, Fabian Gärtner, Maria P Ramnefjell, et al.
Pageof 9